News Feature Channel: Pharmaceuticals

VA and DoD Publish Revised Headache Treatment Advice to Include Recently Approved Therapeutics

American College of Physicians (ACP) — Mon, 28 Oct 2024 17:00:00 EST

The U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) have updated their clinical practice guidelines for the management of headache to include several treatments recently approved by the U.S. Food and Drug Administration (FDA).

Antibody Shows Promise Against Obesity-related Liver Disease and Atherosclerosis in Mice

Federation of American Societies for Experimental Biology (FASEB) — Mon, 28 Oct 2024 15:50:39 EST

Latest research in the FASEB Journal reveals an antibody called bFKB1 improves liver disease and atherosclerosis in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH), which is associated with obesity.

Encrypted Peptides, New Class of Antibiotics, Offer Hope in Fight Against Antibiotic Resistance

Perelman School of Medicine at the University of Pennsylvania — Mon, 28 Oct 2024 10:30:00 EST

In a significant advance against the growing threat of antibiotic-resistant bacteria, , researchers have identified a novel class of antimicrobial agents known as encrypted peptides, which may expand the immune system's arsenal of tools to fight infection.

Study Details Misuse of Scientific Publications by Opioid Industry

Johns Hopkins Bloomberg School of Public Health — Thu, 24 Oct 2024 11:25:57 EST

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that makers and marketers of prescription opioid painkillers misused scientific evidence to advance five common and inaccurate claims about the safety and effectiveness of prescription opioids--including that they were not addictive.

Fading Corporate Survival Prospects: Impact of Co-Selection Bias in Resource Allocation on Strategic Intent

Strategic Management Journal — Thu, 24 Oct 2024 08:40:26 EST

Penicillin Allergy Delabeling in Syphilis Patients Assists in Furthering Treatment

American College of Allergy, Asthma and Immunology (ACAAI) — Thu, 24 Oct 2024 08:00:00 EST

About 10% of Americans believe they are allergic to penicillin, and approximately 90% of those patients are not actually allergic. As a result, those with the penicillin allergy label are often prescribed more toxic, dangerous and expensive antibiotics that might not be necessary or effective.

La Eliminacion Del Etiquetado De La Alergia a La Penicilina en Pacientes Con Sifilis Ayuda a Avanzar en El Tratamiento

American College of Allergy, Asthma and Immunology (ACAAI) — Thu, 24 Oct 2024 08:00:00 EST

Alrededor del 10% de los estadounidenses creen que son alergicos a la penicilina, y aproximadamente el 90% de esos pacientes en realidad no son alergicos.

UM School of Medicine's Margaret M. McCarthy, PhD, Elected as Member of Prestigious National Academy of Medicine

University of Maryland School of Medicine — Wed, 23 Oct 2024 13:00:24 EST

Margaret M. McCarthy, PhD, an internationally-recognized neuroscientist, who is the James and Carolyn Frenkil Dean's Endowed Professor in the University of Maryland School of Medicine's Department of Pharmacology, Physiology, and Drug Development, and Director of the University of Maryland - Medicine Institute of Neuroscience Discovery (UM-MIND), has been elected as a new member of the National Academy of Medicine.

Antibiotics and Antifungals May Slightly Affect Parkinson's Risk, Study Finds

Rutgers University-New Brunswick — Wed, 23 Oct 2024 12:15:52 EST

New research by Rutgers Health researchers highlights a complex relationship between bacteria in the digestive tract and brain health.

LLNL Researchers Discover Promising New Treatment to Counteract the Effects of Fentanyl for Overdose Cases

Lawrence Livermore National Laboratory — Wed, 23 Oct 2024 08:00:00 EST

A team of Lawrence Livermore National Laboratory (LLNL) researchers has discovered a promising new treatment to counteract the effects of fentanyl and related opioids.

Blue-Purple Magic Unlocked: Scutellaria Baicalensis Genome Holds Key to Flavonoid Biosynthesis

Chinese Academy of Sciences — Tue, 22 Oct 2024 11:35:36 EST

A pioneering study has completed the first gap-free genome assembly of Scutellaria baicalensis, a medicinal plant known for its potent therapeutic properties. The research decodes the genetic basis of anthocyanin production, which gives the plant its signature blue-purple flowers, as well as key flavonoid compounds.

Study Combines Woodchips and Biochar to Clean Water of Pharmaceuticals, Nutrients

Mon, 21 Oct 2024 12:20:04 EST

In a new University of Illinois Urbana-Champaign study, researchers show how a simple system using woodchips and a bit of glorified sawdust --- designer biochar --- can dramatically reduce nitrogen, phosphorus, and multiple common drugs in wastewater.

Director of Simmons Cancer Center, UTSW Pharmacology Chair Elected to the National Academy of Medicine

UT Southwestern Medical Center — Mon, 21 Oct 2024 10:50:29 EST

Carlos L. Arteaga, M.D., Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center, and David Mangelsdorf, Ph.D., Chair and Professor of Pharmacology and Professor of Biochemistry, have been elected to the National Academy of Medicine (NAM), one of the highest honors in the fields of health and medicine.

Ibuprofen and Other NSAIDs May Reduce the Risk of Postoperative Delirium

American Society of Anesthesiologists (ASA) — Sun, 20 Oct 2024 09:30:00 EST

Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may help reduce patients' risk of postoperative delirium, according to a study presented at the ANESTHESIOLOGY(r) 2024 annual meeting.

Evergreen Theragnostics Opens CCK2-VIEW, a Phase II Small Cell Lung Cancer Clinical Trial, in the European Union

Evergreen Theragnostics, Inc. — Fri, 18 Oct 2024 06:10:38 EST

Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, focused on providing additional treatment options for cancer patients, is pleased to announce opening of its trial of 68Ga-EVG321 for patients with small cell lung cancer in the European Union, after receiving approval by the European Medicines Agency (EMA) to start recruitment (EUCT ID # 2024-514584-25-00).

Bio X Cell Announces Board of Director Appointments

Bio X Cell — Thu, 17 Oct 2024 05:25:59 EST

Bio X Cell, LLC ("BXC" or the "Company"), the world's leading producer of monoclonal antibodies for pre-clinical in vivo research applications, is pleased to announce the appointments of Alan Hirzel and Kevin Ballinger to its Board of Directors.

CovarsaDx Welcomes Rich Masino as Senior Director of Strategic Partnerships and Business Development

CovarsaDx — Tue, 15 Oct 2024 10:10:46 EST

CovarsaDx, a clinical research organization at the forefront of in vitro diagnostics (IVD) and medical device trials, has appointed Rich Masino as senior director of strategic partnerships and business development. Bringing over 30 years of experience in biotech, pharma, and medical device diagnostics, Masino will focus on driving growth and forging strategic partnerships across CovarsaDx and ZoaDx, while reporting directly to the company's chief executive officer (CEO).

Novel Study Uncovers Health Benefits of Red Clover Seed Oil

Chinese Academy of Sciences — Sat, 12 Oct 2024 11:05:51 EST

A research team has identified a wealth of bioactive compounds in red clover (Trifolium pratense ) seeds and their oil, positioning them as a promising source for functional ingredients in food and health care products.

U-M Drug Cost Researcher Available to Comment on $2 Medicare Drug List

Michigan Medicine - University of Michigan — Thu, 10 Oct 2024 06:05:14 EST

Dual Immunotherapy Plus Chemotherapy Benefits Specific Subset of Patients with Lung Cancer

University of Texas MD Anderson Cancer Center — Wed, 09 Oct 2024 11:00:00 EST

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population.